Using a dataset of 594 CRC patients/samples from the TCGA Pan Cancer Atlas, we looked at the percentage of alterations present in HDAC2, CIITA, and B2M based on mutations, mRNA expression levels, structural variants, and amplifications (Figure 9). This evidence concerns the gene HDAC2 and cancer.